COIOSDeep risk insights through multi-disciplinary research across the globe
A bright stationery store interior with shelves of greeting cards and office supplies
Item refines Peer-reviewed Added

Pancreatic cancer risk on GLP-1 drugs depends on the diabetes drug compared

Pancreatic cancer was less common in GLP-1 starters than in starters of four other diabetes classes, while against insulin the paper reports a lower hazard but a higher absolute risk.

In the TriNetX health record network, adults with type 2 diabetes starting a GLP-1 drug were compared with starters of six other diabetes classes. Pancreatic cancer was 30% to 39% more common among starters of metformin, sulfonylureas, thiazolidinediones and DPP-4 inhibitors than among GLP-1 starters. Against insulin the paper reports a lower hazard for GLP-1 users but a higher absolute risk, 0.15% against 0.11%.

Why it is interesting: The direction of the pancreatic cancer signal depends on which diabetes drug the comparison is made against.

Source
Journal of Gastrointestinal Cancer, 16 September 2026
Paper
Long-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score-Matched Retrospective Cohort Study Using the TriNetX Network
Authors
Kazi MAI, Khan J, Mufarrih SM, Siddiqui M, Ansari HUH, Ahmed M et al.
DOI
10.1007/s12029-026-01523-w
Type
Peer-reviewed article
Design
Retrospective new-user cohort in the TriNetX federated EHR network, adults with type 2 diabetes, six separate 1:1 propensity-score-matched comparisons on 39 covariates, outcome incident pancreatic cancer 365-7,300 days after index
Verdict
Refines prior evidence
Driver
Cancer
Driver
Obesity, diabetes and GLP-1

Other drivers in Health today